Physician profile
Pejman E Cohan
NPI 1225064884
$33,949.35
in general payments reported to CMS, 2019-2025
61 companies · $1,760 in 2025
The $1,760 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $1,184 · 2021: $6,003 · 2022: $1,957 · 2023: $1,777 · 2024: $1,607 · 2025: $1,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,917 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,917.34 |
| Education | $225.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $13,627.89 | 2019-2023 | Tepezza |
| Antares Pharma, INC. | $4,143.39 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $2,889.70 | 2020-2025 | Isturisa, Signifor Lar |
| Chiasma, INC. | $1,800.00 | 2021 | |
| Novo Nordisk INC | $1,772.34 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,121.23 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $993.69 | 2019-2025 | Evenity, Repatha, Tepezza |
| Mannkind Corporation | $825.97 | 2019-2025 | Afrezza |
| Radius Health, INC. | $703.53 | 2019-2025 | Tymlos |
| Corcept Therapeutics | $685.19 | 2019-2025 | Korlym |
| Ibsa Pharma INC. | $494.53 | 2019-2025 | Licart, Tirosint, Flector |
| Abbvie INC. | $451.58 | 2019-2023 | Synthroid |
| Abbott Laboratories | $449.03 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $389.92 | 2019-2025 | Tradjenta, Synjardy, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $328.00 | 2021-2025 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,651,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pejman Cohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.